Stocksigma LogoStocksigma Logo

Medicamen Biotech FY26 BRSR Highlights Strong Export Reliance and Environmental Compliance

Medicamen Biotech reported a FY26 turnover of ₹178.84 crore and PAT of ₹9.41 crore. The pharmaceutical manufacturer generates 80% of sales from exports

Medicamen Biotech FY26 BRSR Highlights Strong Export Reliance and Environmental Compliance

Medicamen Biotech Ltd · Others (Uncategorized) · 03 Sept 2026, 10:49 pm

Medicamen Biotech FY26 BRSR Highlights Strong Export Reliance and Environmental Compliance Medicamen Biotech reported a FY26 turnover of ₹178.84 crore and PAT of ₹9.41 crore. The pharmaceutical manufacturer generates 80% of sales from exports across 35 countries via three domestic facilities. Operations maintained zero safety incidents, zero product recalls, and zero liquid discharge. The company invested 22% of capital in R&D and increased MSME sourcing to 23%. CSR spending reached ₹25.20 lakh, with the unspent ₹6.13 lakh transferred to Schedule VII funds. A nominal ₹7,080 NSE penalty for delayed shareholding pattern filings was fully paid and regularized.

Original exchange filing (PDF)

More announcements from Medicamen Biotech Ltd

All Medicamen Biotech Ltd announcements